FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
This article was originally published in The Tan Sheet
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
You may also be interested in...
FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription
A majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee members recommended against lowering the body mass index for clinical trials involving weight-loss drugs
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.